1022 related articles for article (PubMed ID: 11122857)
1. New developments in melanoma genetics.
Hayward N
Curr Oncol Rep; 2000 Jul; 2(4):300-6. PubMed ID: 11122857
[TBL] [Abstract][Full Text] [Related]
2. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
[TBL] [Abstract][Full Text] [Related]
5. [Familial malignant melanoma].
Ueda M
Nihon Rinsho; 2000 Jul; 58(7):1381-4. PubMed ID: 10921309
[TBL] [Abstract][Full Text] [Related]
6. Reply to: "The absence of multiple atypical nevi in germline CDKN2A mutations".
Soura E; Stratigos AJ; Tsao H
J Am Acad Dermatol; 2016 Oct; 75(4):e159. PubMed ID: 27646764
[No Abstract] [Full Text] [Related]
7. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of familial cutaneous melanoma.
Haluska FG; Hodi FS
J Clin Oncol; 1998 Feb; 16(2):670-82. PubMed ID: 9469357
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
[TBL] [Abstract][Full Text] [Related]
11. The absence of multiple atypical nevi in germline CDKN2A mutations: Comment on "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome".
Ipenburg NA; Gruis NA; Bergman W; van Kester MS
J Am Acad Dermatol; 2016 Oct; 75(4):e157. PubMed ID: 27646763
[No Abstract] [Full Text] [Related]
12. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
[TBL] [Abstract][Full Text] [Related]
13. A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.
van der Velden PA; Sandkuijl LA; Bergman W; Hille ET; Frants RR; Gruis NA
Genome Res; 1999 Jun; 9(6):575-80. PubMed ID: 10400925
[TBL] [Abstract][Full Text] [Related]
14. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
[TBL] [Abstract][Full Text] [Related]
15. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
16. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
17. Detection of a rare CDKN2A intronic mutation in a Hungarian melanoma-prone family and its role in splicing regulation.
Balogh K; Széll M; Polyánka H; Pagani F; Bussani E; Kemény L; Oláh J
Br J Dermatol; 2012 Jul; 167(1):131-3. PubMed ID: 22292911
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
19. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
[TBL] [Abstract][Full Text] [Related]
20. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
